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BACKGROUND: Dobutamine stress echocardiography is widely used 
to test for ischemia in patients with stable coronary artery disease. 
In this analysis, we studied the ability of the prerandomization stress 
echocardiography score to predict the placebo-controlled efficacy of 
percutaneous coronary intervention (PCI) within the ORBITA trial (Objective 
Randomised Blinded Investigation With Optimal Medical Therapy of 
Angioplasty in Stable Angina).
METHODS: One hundred eighty-three patients underwent dobutamine 
stress echocardiography before randomization. The stress echocardiography 
score is broadly the number of segments abnormal at peak stress, with 
akinetic segments counting double and dyskinetic segments counting triple. 
The ability of prerandomization stress echocardiography to predict the 
placebo-controlled effect of PCI on response variables was tested by using 
regression modeling.
RESULTS: At prerandomization, the stress echocardiography score was 
1.56±1.77 in the PCI arm (n=98) and 1.61±1.73 in the placebo arm 
(n=85). There was a detectable interaction between prerandomization 
stress echocardiography score and the effect of PCI on angina frequency 
score with a larger placebo-controlled effect in patients with the highest 
stress echocardiography score (P
interaction=0.031). With our sample size, we 
were unable to detect an interaction between stress echocardiography 
score and any other patient-reported response variables: freedom from 
angina (Pinteraction=0.116), physical limitation (Pinteraction=0.461), quality of 
life (Pinteraction=0.689), EuroQOL 5  quality-of-life score (Pinteraction=0.789), or 
between stress echocardiography score and physician-assessed Canadian 
Cardiovascular Society angina class (Pinteraction=0.693), and treadmill exercise 
time (Pinteraction=0.426).
CONCLUSIONS: The degree of ischemia assessed by dobutamine stress 
echocardiography predicts the placebo-controlled efficacy of PCI on 
patient-reported angina frequency. The greater the downstream stress 
echocardiography abnormality caused by a stenosis, the greater the reduction 
in symptoms from PCI.
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The primary results of the ORBITA trial (Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina) 
showed a smaller-than-expected effect size of percuta-
neous coronary intervention (PCI) in comparison with 
placebo in single-vessel stable coronary artery disease 
on the primary end point of change in treadmill exer-
cise time.1 These findings of ORBITA contrasted with 
those of previous unblinded trials which showed that 
patients aware that they had received PCI had a clear 
improvement in exercise time, reduction in angina, and 
improved quality of life, in comparison with patients 
aware that they had not received PCI.2–7
Although there was no significant difference be-
tween PCI and placebo groups in the patient-reported 
and physician-assessed symptom and quality-of-life end 
points, ischemia as assessed by dobutamine stress echo-
cardiography (DSE) wall motion score index showed a 
clear reduction with PCI (prerandomization to follow-
up increment: –0.07 in the PCI arm versus 0.02 in the 
placebo arm, P<0.0001).
Building on the primary analysis, the physiology-strati-
fied analysis of ORBITA found that the severity of ischemia 
assessed by prerandomization fractional flow reserve (FFR) 
and instantaneous wave-free ratio (iFR) predicted the 
degree of improvement of ischemia as assessed by DSE 
score in the 196 patients with prerandomization invasive 
physiology data.8 However, there was no detectable in-
teraction between invasive physiology and the placebo-
controlled effect of PCI on symptoms or exercise time. 
Again, these findings contrasted with those of unblinded 
studies.9,10 Without placebo control, and with staff aware 
of measurements, there was a clear relationship between 
FFR or iFR and symptoms or exercise time.
In previous data sets11 and in ORBITA, PCI almost com-
pletely normalizes any left ventricular wall motion abnor-
malities detected by DSE. However, there has been no 
assessment of whether the magnitude of baseline stress 
echocardiography ischemia determines the magnitude 
of symptom relief from PCI, beyond any placebo effect.
In the present analysis of patients who had preran-
domization DSE data, we stratified by the prerandom-
ization stress echocardiography score and assessed its 
impact on the placebo-controlled effect of PCI on the 
primary and secondary end points of ORBITA.
METHODS
The data, analytical methods, and study materials will not be 
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure. The London 
Central Research Ethics Committee (reference 13/LO/1340) 
approved the study and written consent was obtained from 
all patients before their enrollment.
Study Design
The design of the ORBITA trial has been reported previously.1 
In brief, the ORBITA trial was a double-blind randomized, 
controlled trial comparing PCI with a placebo procedure in 
patients with stable angina and angiographically severe sin-
gle-vessel coronary artery disease. Intensive medical therapy 
was given to both groups. Before randomization, patients 
had assessment of symptom and quality-of-life question-
naires, cardiopulmonary exercise testing using a smoothed 
modified Bruce protocol, DSE, and FFR and iFR measurement.
Blinding and Randomization
Patients were randomly assigned 1:1 to PCI or a placebo 
procedure. Patients and the medical team outside the cath-
eterization laboratory were blinded to treatment allocation as 
previously described.1
Study End Points and Follow-Up
At the end of the 6-week blinded period, patients returned 
for the repeat of all prerandomization tests including symp-
tom and quality-of-life questionnaires, cardiopulmonary exer-
cise testing, and DSE.
DSE Assessment
Patients were instructed to omit β-blockers for at least 24 
hours before DSE. The test was performed by a physician and 
Clinical Perspective
What Is New?
• This report of ORBITA (Objective Randomised 
Blinded Investigation With Optimal Medical Ther-
apy of Angioplasty in Stable Angina), stratified 
by ischemia assessed by stress echocardiography, 
provides the first placebo-controlled evidence of 
an association between stress echocardiography 
ischemia and the magnitude of placebo-controlled 
benefit attributable to percutaneous coronary 
intervention.
• Prerandomization stress echocardiography score pre-
dicts the placebo-controlled effect of percutaneous 
coronary intervention on angina frequency score.
What Are the Clinical Implications?
• Although in ORBITA there was no detectable pla-
cebo-controlled reduction in angina frequency with 
percutaneous coronary intervention, this analysis 
shows that the greater the prerandomization stress 
echocardiography score, the greater the placebo-
controlled reduction in angina.
• For patients with a stress echocardiography score 
of at least 1, there is a clear placebo-controlled 
reduction in patient-reported symptoms with per-
cutaneous coronary intervention.
• This dependence of symptomatic relief on preran-
domization ischemia was evident with stress echo-
cardiography, but not with invasive physiology.
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a sonographer. The patient, physician, and sonographer were 
all blinded to allocation arm.
Echocardiography was performed using contrast for all 
studies. The contrast agent used was a commercially avail-
able sulfur hexafluoride microbubble preparation, SonoVue 
(Bracco Imaging SpA). This agent was administered in 0.3-
mL bolus doses intravenously for each image acquisition 
followed by 1 to 2 mL of saline flush. After acquisition of 
resting images to exclude significant valvular disease, intrave-
nous dobutamine was infused at a starting dose of 10 µg·kg–
1·min–1 followed by increasing doses of 20 µg·kg–1·min–1, 30 
µg·kg–1·min–1, up to a maximum of 40 µg·kg–1·min–1 in 3-min-
ute stages. Intravenous atropine was administered in 300-μg 
boluses up to a maximum of 1200 μg for those patients not 
achieving 85% of the predicted maximal heart rate. Images 
were taken in the apical 2-chamber, 3-chamber, 4-chamber, 
and parasternal short-axis views at baseline, low-dose stress, 
high-dose stress, and recovery.
DSE Reporting
Analysis was also performed with reporters blinded to treat-
ment allocation and phase (prerandomization or follow-up), 
using an online reporting tool.
Each scan was examined twice by 6 imaging consultants 
(R.A., D.P.F., G.C., G.K., J.S., and N.G.K.) who were blinded to 
treatment allocation, time point of the scan, their colleagues’ 
opinions, and their own first opinion.
Stress echocardiography results are presented in a man-
ner that represents the number of hypokinetic segments 
(with akinetic segments scoring double, dyskinetic segments 
scoring triple, and aneurysmal segments scoring quadruple). 
The left ventricle was divided into the standard 17-segment 
model. Wall motion was scored as follows: normal=0, hypoki-
netic=1, akinetic=2, dyskinetic=3, or aneurysmal=4. Individual 
wall abnormality scores at peak stress were summed. Both 
opinions from all 6 consultants were averaged. The stress 
echocardiography score8 can be broadly converted to clas-
sical wall motion score index as follows: wall motion score 
index=1+(stress echocardiography score)/17. More details are 
provided in the online-only Data Supplement.
Statistical Analysis
Summary statistics were presented as appropriate for baseline 
characteristics. To assess the observer variability of the stress 
echocardiography score, we calculated the mean inter- and 
intraobserver absolute differences.12
Models were fitted for each end point. Models using ordi-
nary least squares were used for the continuous variables: 
Seattle Angina Questionnaire (SAQ) physical limitation and 
quality-of-life score, EuroQOL 5 (EQ-5D-5L) descriptive score, 
and exercise time. Proportional odds logistic models were 
used for ordinal variables: SAQ angina frequency score and 
freedom from angina, and Canadian Cardiovascular Society 
angina class. For each of the components of the SAQ, and 
freedom from angina, as well, a higher score represents a bet-
ter health state; therefore, an odds ratio >1 suggests that a 
better health state was achieved with PCI over placebo.
To assess the interaction of prerandomization stress echo-
cardiography score with each continuous and categorical out-
come variable, the follow-up value was modeled conditioned 
on the prerandomization value transformed by a restricted 
cubic spline with 3 parameters, and randomization arm. A 
model was then fitted with prerandomization stress echo-
cardiography score interacting with the randomization arm 
with a restricted cubic spline with 3 parameters. Knots were 
placed at the standard positions of 25th, 50th, and 75th per-
centiles of the covariate distribution. Therefore, the shape 
of the effect was allowed to vary over treatments.13 Graphs 
are shown of the end points against prerandomization stress 
echocardiography score. The contrast between the arms 
was generated with an adjustment for the median value of 
the prerandomization value. The vertical coordinate of the 
graphs is the difference in end value between the 2 arms, 
conditioned on their prerandomization value. We report the 
interaction with treatment as the P value (Pinteraction) from the 
combined main effect and interaction effect.
Analyses were performed using the open-source statistical 
environment R,14 with the package rms for regression model-
ing15 and ggplot2 for graphs.16
RESULTS
Prerandomization stress echocardiography scores were 
available for 183 patients (98 PCI and 85 placebo) of 
the 200 patients randomly assigned in ORBITA. Of the 
remaining 17 patients, 1 had poor-quality echocardio-
graphic imaging windows, 6 had a previous adverse 
reaction to dobutamine (5 minor but limiting reac-
tions, 1 severe life-threatening reaction), 6 had a clini-
cal contraindication to dobutamine administration, 
and in 4 there were logistical reasons as to why the 
test was not performed.
Patient Demographics
Table 1 shows the patient demographic data. The ma-
jority of patients had normal left ventricular systolic 
function (94.9% in the PCI arm and 90.6% in the pla-
cebo arm). Median angina duration was 5 months in 
the PCI arm (interquartile range, 4–10) and 6 months in 
the placebo arm (interquartile range, 4–9).
Procedural Demographics
Table 2 shows the procedural demographic data. The ma-
jority of lesions were in the left anterior descending artery 
(68.4% PCI and 69.4% placebo); 16.3% (16/98) patients 
in the PCI arm and 11.8% (10/85) patients in the placebo 
arm had serial lesions in a single coronary artery. The mean 
diameter stenosis by quantitative coronary angiography 
was 64.3±13.9% in the PCI arm and 64.1±13.4% in the 
placebo arm. The mean prerandomization stress echo-
cardiography score was 1.56±1.77 in the PCI arm and 
1.61±1.73 in the placebo arm. The distribution of pre-
randomization stress echocardiography scores is shown in 
Figure I in the online-only Data Supplement. The preran-
domization mean stress wall motion score for each seg-
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ment as associated with target vessel coronary territory 
is shown in Table I in the online-only Data Supplement. 
The mean inter- and intraobserver absolute differences of 
the stress echocardiography score were 1.4 and 1.0 stress 
echocardiography units, respectively. The mean FFR was 
0.69±0.16 for the PCI arm and 0.69±0.16 for the pla-
cebo arm, and the mean iFR was 0.76±0.22 for the PCI 
arm and 0.77±0.20 for the placebo arm. After interven-
tion with drug-eluting stents implanted in the PCI arm, 
the mean FFR increased to 0.90±0.05 and iFR increased to 
0.95±0.04. The change in stress echocardiography score 
from prerandomization to follow-up in 161 patients with 
stress echocardiography data at both time points is shown 
in Figure II in the online-only Data Supplement.
Table 1. Patient Demographics at Enrollment
Demographics
PCI (n=98)
n (%)
Placebo
(n=85)  
n (%)
Complete 
Group 
(n=183)  
n (%)
Age, y
  Mean (SD) 65.9±9.6 65.8±8.5 65.9±9.1
  Median (IQR) 66 (60–74) 67 (60–71) 66 (60–73)
Male 68 (69.4) 65 (76.5) 133 (72.7)
Hypertension 65 (66.3) 58 (68.2) 123 (67.2)
Hypercholesterolemia 74 (75.5) 57 (67.1) 131 (71.6)
Diabetes mellitus 14 (14.3) 19 (22.4) 33 (18.0)
Previous MI 4 (4.1) 7 (8.2) 11 (6.0)
Previous PCI 9 (9.2) 15 (17.6) 24 (13.1)
CCS class
  I 2 (2.0) 3 (3.5) 5 (2.7)
  II 61 (62.2) 48 (56.4) 109 (59.6)
  II 35 (35.7) 34 (40.0) 69 (37.7)
Left ventricular systolic function
  Normal 93 (94.9) 77 (90.6) 170 (92.9)
  Mild impairment 3 (3.1) 5 (5.9) 8 (4.4)
  Moderate impairment 2 (2.0) 3 (3.5) 5 (2.7)
  Severe impairment 0 (0) 0 (0) 0 (0)
Angina duration, mo
  Mean (SD) 9.7 (16.2) 8.4 (7.7) 9.1 (12.9)
  Median (IQR) 5 (4–10) 6 (4–9) 6 (4–9)
Preenrollment clinical positive 
functional test
52 (53.1) 36 (42.4) 88 (48.1)
  ETT 24 (24.5) 15 (17.6) 39 (21.3)
  MIBI 10 (10.2) 8 (9.4) 18 (9.8)
  DSE 18 (18.4) 12 (14.1) 30 (16.4)
  MRI perfusion 0 (0) 1 (1.2) 1 (0.5)
CCS indicates Canadian Cardiovascular Society angina class; DSE, dobutamine 
stress echocardiography; ETT, exercise tolerance test; IQR, interquartile range; 
MI, myocardial infarction; MIBI, nuclear medicine myocardial perfusion scan; 
MRI, magnetic resonance imaging; and PCI, percutaneous coronary intervention.
Table 2. Procedural Demographics
Demographics
PCI (n=98)  
n (%)
Placebo
(n=85) n (%)
Complete 
Group 
(n=183) n (%)
Target vessel
  Left anterior 
descending
67 (68.4) 59 (69.4) 126 (68.9)
  Right coronary 16 (16.3) 13 (15.3) 29 (15.8)
  Circumflex 9 (9.2) 9 (10.6) 18 (9.8)
  First obtuse marginal 3 (3.1) 0 (0) 3 (1.6)
  First diagonal 2 (2.0) 2 (2.4) 4 (2.2)
  Intermediate 1 (1.0) 2 (2.4) 3 (1.6)
Serial lesions 16 (16.3) 10 (11.8) 26 (14.2)
No. pts with diameter 
stenosis ≥50% by QCA
84 (85.7) 73 (85.9) 157 (85.8)
No. pts with area 
stenosis ≥70% by QCA
92 (93.9) 78 (91.8) 170 (92.9)
Diameter stenosis by QCA
  Mean (SD) 64.3±13.9 64.1±13.4 64.2±13.6
  Median (IQR) 63.9 (53.5–74.1) 62.8 (53.2–74.9) 63.4 (53.3–74.2)
Prerandomization stress echocardiography score
  Mean (SD) 1.56±1.77 1.61±1.73 1.58±1.75
  Median (IQR) 1 (0.42–2.15) 1 (0.42–2.00) 1 (0.42–2.08)
FFR n=97 n=82 n=179
  Mean (SD) 0.69±0.16 0.69±0.16 0.69±0.16
  Median (IQR) 0.72 (0.57–0.82) 0.73 (0.59–0.80) 0.72 (0.58–0.81)
iFR n=97 n=84 n=181
  Mean (SD) 0.76±0.22 0.77±0.20 0.76±0.21
  Median (IQR) 0.85 (0.68–0.92) 0.85 (0.70–0.89) 0.85 (0.69–0.90)
No. pts with FFR 
≤0.80
n=97 n=82 n=179
71 (73.2) 63 (76.8) 134 (74.9)
No. pts with iFR ≤0.89 n=97 n=84 n=181
63 (64.9) 62 (73.8) 125 (69.1)
Stent length (mm)
  Median (IQR) 24 (18–33) NA NA
Stent diameter (mm)
  Median (IQR) 3 (2.75–3.5) NA  NA
FFR post PCI n=96 NA NA
  Mean (SD) 0.90±0.05   
  Median (IQR) 0.90 (0.87–0.93)   
iFR post PCI n=97 NA NA
  Mean (SD) 0.95±0.04   
  Median (IQR) 0.95 (0.92–0.97)   
No. pts with post 
FFR>0.80
n=96 NA NA
91 (94.8)
No. pts with post 
iFR>0.89
n=97 NA NA
94 (96.9)
FFR indicates fractional flow reserve; iFR, instantaneous wave-free ratio; IQR, 
interquartile range; NA, not available; PCI, percutaneous coronary intervention; 
pts, patients; and QCA, quantitative coronary angiography.
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Relationship Between FFR and iFR and 
Stress Echocardiography Score
Prerandomization FFR or iFR and DSE data were avail-
able in 179 patients and 181 patients, respectively (in 
2 patients we were unable to elicit a hyperemic re-
sponse to adenosine and, therefore, only iFR data are 
available). Figure  1A shows the relationship between 
prerandomization FFR and prerandomization stress 
echocardiography score. As the stress echocardiogra-
phy score became larger with a greater number of isch-
emic myocardial segments, the FFR value decreased, 
therefore showing a greater degree of ischemia (Pcor-
relation<0.0001). At a stress echocardiography score of 
0 (normal), the mean FFR was 0.76±0.17 (n=16). For 
scores intermediate between 0 and 1, mean FFR was 
0.72±0.14 (n=72); at ≥1 to <2, 0.71±0.12 (n=45); at 
≥2 to <3, 0.65±0.17 (n=21); and at ≥3, 0.55±0.18 
(n=25). Figure 1B shows the relationship between pre-
randomization iFR and prerandomization stress echo-
cardiography score. Similarly, as the stress echocardiog-
raphy score became larger with a greater number of 
ischemic myocardial segments, the iFR also decreased, 
showing a greater degree of ischemia (P<0.0001). At a 
stress echocardiography score of 0 (normal), the mean 
iFR was 0.85±0.16 (n=16). For scores intermediate be-
tween 0 and 1, mean iFR was 0.82±0.16 (n=73); at 
≥1 to <2, 0.80±0.16 (n=45); at ≥2 to <3, 0.67±0.26 
(n=21); and at ≥3, 0.57±0.27 (n=26).
Patient-Reported Symptoms
SAQ Angina Frequency Score and Freedom From 
Angina
Paired SAQ angina frequency data were available for 
176 patients in the stress echocardiography–stratified 
analysis of ORBITA (96 in the PCI arm and 80 in the 
placebo arm). Overall, there was little evidence that PCI 
improved angina frequency score more than placebo 
(odds ratio [OR], 1.68 [95% CI, 0.96–2.95], P=0.069) 
in this DSE subset (Table 3). However, there was a de-
tectable interaction between prerandomization stress 
echocardiography score and the effect of PCI on an-
gina frequency score with a larger placebo-controlled 
effect of PCI in patients with the highest stress echocar-
diography score (Pinteraction=0.031; Figure 2). This interac-
tion resulted in patients with a prerandomization stress 
echocardiography score of ≥1 being more likely to have 
a lower angina frequency score with PCI than with pla-
cebo (OR, 3.18 [95% CI, 1.38–7.34], P=0.007; Table II 
in the online-only Data Supplement).
Paired angina freedom data were available for 
175 patients in the stress echocardiography–stratified 
analysis of the ORBITA (95 in the PCI arm and 80 in 
the placebo arm). PCI was more likely to result in pa-
tient-reported freedom from angina than placebo (OR, 
3.01 [95% CI, 1.51–6.03], P=0.002) in this DSE sub-
set (Table 3). There was no detectable interaction be-
tween prerandomization stress echocardiography score 
and the effect of PCI on freedom from angina (Pinterac-
tion=0.116; Figure 3). Patients with a prerandomization 
stress echocardiography score of ≥1 were more likely 
to be free from angina with PCI than with placebo (OR, 
4.62 [95% CI, 1.70–12.60], P=0.003; Table III in the 
online-only Data Supplement).
SAQ Physical Limitation Score and Quality-of-Life 
Score and EQ-5D-5L Score
Paired SAQ physical limitation data, SAQ quality of life, 
and EQ-5D-5L data were available for 171 patients (93 
in the PCI arm and 78 in the placebo arm), 175 patients 
(96 in the PCI arm and 79 in the placebo arm), and 175 
Figure 1. Relationship between prerandomization stress echocardiography score and prerandomization FFR and iFR. 
A, Relationship between prerandomization stress echocardiography score and prerandomization FFR. B, Relationship between prerandomization stress echocar-
diography score and prerandomization iFR. echo indicates echocardiography; FFR, fractional flow reserve; and iFR, instantaneous wave-free ratio.
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patients (96 in the PCI arm and 79 in the placebo arm), 
respectively, in the stress echocardiography–stratified 
analysis of the ORBITA. There was no evidence that PCI 
improved physical limitation score more than placebo 
(1.02 [95% CI, –4.65 to 6.68], P=0.724 in this DSE 
subset, quality-of-life score more than placebo (0.14 
[95% CI, –5.80 to 6.07], P=0.964 in this DSE subset 
or EQ-5D-5L quality-of-life score more than placebo 
(–0.007 [95% CI, –0.048 to 0.034], P=0.73; Table 3). 
There was no detectable interaction between preran-
domization stress echocardiography score and the ef-
fect of PCI on physical limitation score (Pinteraction=0.461; 
Figure 4), quality-of-life score (Pinteraction=0.689; Figure III 
in the online-only Data Supplement) or quality of life as 
assessed by EQ-5D-5L (Pinteraction=0.789; Figure IV in the 
online-only Data Supplement).
Physician-Assessed Symptoms
Paired Canadian Cardiovascular Society class data were 
available for 179 patients (98 in the PCI arm and 81 
in the placebo arm). There was no evidence that PCI 
improved Canadian Cardiovascular Society class more 
than placebo (OR, 0.85 [95% CI, 0.49–1.47], P=0.552; 
Table 3). There was no detectable interaction between 
prerandomization stress echocardiography score and 
the effect of PCI on Canadian Cardiovascular Society 
class (Pinteraction=0.693; Figure V in the online-only Data 
Supplement).
Exercise Time
Paired exercise time data were available for 177 patients 
(97 in the PCI arm and 80 in the placebo arm). The esti-
mated effect of PCI over placebo on exercise time using 
regression modeling was 17.0 seconds (95% CI, –8.22 
to 42.2; P=0.19) in this DSE subset (Table 3). There was 
no detectable interaction between prerandomization 
stress echocardiography score and the effect of PCI on 
exercise time (Pinteraction=0.426; Figure 5). There was no 
evidence that patients with a prerandomization stress 
echocardiography score of ≥1 were more likely to have 
more exercise time improvement with PCI that with pla-
Table 3. End Point Analysis
End Point
ANCOVA Estimate With the Covariate 
Modeled as a Restricted Cubic Spline 
(PCI Over Placebo)
Primary end point:
  Exercise time 17.01 s (95% CI, –8.22 to 42.24; 
P=0.185)
Secondary end points:
  EQ-5D-5L –0.007 (95% CI, –0.048 to 0.034; 
P=0.730)
  SAQ physical limitation score 1.02 (95% CI, –4.65 to 6.68; P=0.724)
  SAQ quality-of-life score 0.14 (95% CI −5.80 to 6.07; P = 0.964)
 Logistic (Proportional Odds) Ordinal 
Regression Model Estimate (PCI Over 
Placebo)
  SAQ angina frequency score OR, 1.68 (95% CI, 0.96 to 2.95;P=0.069)
  SAQ freedom from angina OR, 3.01 (95% CI, 1.51 to 6.03; 
P=0.002)
  CCS class OR, 0.85 (95% CI, 0.49 to 1.47; 
P=0.552)
Treatment effect estimates obtained using modeling. The follow-up value is 
dependent on prerandomization value and treatment arm. ANCOVA indicates 
analysis of covariance; CCS, Canadian Cardiovascular Society angina class; EQ-
5D-5L, EuroQOL 5 questionnaire; OR, odds ratio; PCI, percutaneous coronary 
intervention; and SAQ, Seattle Angina Questionnaire.
Figure 2. Relationship of treatment difference in Seattle Angina Ques-
tionnaire (SAQ) angina frequency score at follow-up to prerandomiza-
tion stress echocardiography score by randomization arm. 
There is a significant interaction between stress echocardiography score and 
Seattle Angina Frequency score with a progressive tendency for larger effects 
on angina frequency score with higher stress echocardiography score  
(Pinteraction=0.031). echo indicates echocardiography; and PCI, percutaneous 
coronary intervention.
Figure 3. Relationship of treatment difference in freedom from angina 
and prerandomization stress echocardiography by randomization arm. 
There is no discernible dependence on prerandomization stress echocardiogra-
phy score. echo indicates echocardiography; and PCI, percutaneous coronary 
intervention.
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cebo (18.4 seconds [95% CI, –18.3 to 55.1], P=0.322; 
Table IV in the online-only Data Supplement).
DISCUSSION
This is the first placebo-controlled analysis of the relation-
ship between ischemia assessed by DSE and the efficacy 
of PCI in stable coronary artery disease. The prerandom-
ization stress echocardiography score significantly pre-
dicted the placebo-controlled impact of PCI on patient-
reported angina frequency. The greater the ischemia, the 
greater the symptom improvement. Second, although a 
greater proportion of patients became free from angina 
in the PCI arm than in the placebo arm, there was no evi-
dence of interaction between this effect and the preran-
domization stress echocardiography score. Finally, there 
was strong correlation between prerandomization stress 
echocardiography score and invasive physiology mea-
sured by FFR and iFR. The greater the number of ischemic 
regional wall segments, the lower the FFR and iFR.
We propose an explanation for these and previously 
reported results from the ORBITA trial.1,8 The progres-
sive decline in strengths of association may result from 
the sequence of steps in the pathway of ischemia, with 
the signal becoming increasingly dilute at later steps in 
the chain (Figure 6). PCI immediately relieves the angio-
graphic stenosis (step A). As a result, the intracoronary 
physiology improves (step B). This in turn can reduce 
myocardial ischemia, resolving wall motion abnormali-
ties (step C). Angina, which is presumably a sensation 
arising from ischemia, can be alleviated by this and re-
ported by the patient (step D). The physician, who relies 
on the patient’s verbal and nonverbal cues, is one step 
further removed (step E).
In the primary analysis of ORBITA,1 PCI had an ex-
tremely clear effect on anatomy (step A, P< 0.001 for 
anatomical stenosis). There was a very clear effect on 
physiology (step B, P< 0.001 for FFR and P< 0.001 for 
iFR). The effect on myocardial wall motion abnormality 
was still clear (step C, P< 0.001). One step further, and 
there was no longer a clear effect on angina (step D), 
with the preplanned analysis of SAQ angina frequency 
showing no detectable change (P=0.260) and a post 
hoc analysis showing a clearer effect on the dichoto-
mous end point of freedom from angina (P=0.006).8
Although the relatively weak effects on steps D to 
E in Figure 6 were a surprise in the context of exten-
sive previous experience,2,7,17,18 the previous experience 
was unblinded. Clinical staff are trained to interpret 
the information in steps A, B, and C and explain to the 
patient that the problem has been resolved. Therefore, 
the impact of reassurance alone and simply being told 
that their lesion was not flow-limiting dramatically re-
duced angina rates from 88% to 54% in the DEFER trial 
(Deferral of PTCA Versus Performance of PTCA)  and 
64% to 15% in the FAME-2 trial (Fractional Flow Re-
serve-Guided Percutaneous Coronary Intervention Plus 
Optimal Medical Treatment Versus Optimal Medical 
Treatment Alone in Patients With Stable Coronary Ar-
tery Disease).17,19 An unblinded PCI procedure gives this 
reassurance, that there is now no significant lesion, but 
also gives patients an expectation that the symptoms 
were attributable to the treated lesion and should now 
resolve. Because of this powerful reassurance effect, it 
is not possible to gauge how much of the symptom 
relief from unblinded PCI is purely attributable to the 
physiological effect of stenosis relief20–22 and how much 
may be attributable to the placebo component of un-
blinded PCI.7,18
Figure 4. Relationship of treatment difference in Seattle Angina Ques-
tionnaire (SAQ) physical limitation score and prerandomization stress 
echocardiography by randomization arm. 
There is no discernible dependence on prerandomization stress echocar-
diography score. echo indicates echocardiography; and PCI, percutaneous 
coronary intervention.
Figure 5. Relationship of treatment difference in exercise time and 
prerandomization stress echocardiography by randomization arm. 
There is no discernible dependence on prerandomization stress echocardiogra-
phy score. echo indicates echocardiography; and PCI, percutaneous coronary 
intervention.
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This stress echocardiography–stratified analysis shows 
the link between stress-induced myocardial wall motion 
abnormalities (step C) and patient-reported angina fre-
quency (step D). The greater the ischemia on DSE, the 
greater the placebo-controlled angina relief from PCI.
The invasive physiology measures, FFR and iFR, are 
further upstream (step B). This may explain why they 
were not as strongly associated as DSE with the mag-
nitude of placebo-controlled angina relief from PCI.8 
Physiological features other than the transstenotic 
pressure gradient may affect whether the myocardium 
experiences sufficient ischemia to manifest stress echo-
cardiography abnormalities or symptoms. For example, 
there may be microvascular dysfunction or differential 
sensitivity of the myocardium to intracoronary pressure. 
Many patients with obstructive epicardial stenoses also 
have microvascular disease. ORBITA did not acquire 
coronary microvascular function to distinguish between 
the various possibilities.
Another alternative proposed explanation might be 
that the conventional cut points for ischemia with FFR 
and iFR may not correspond to those of stress echo-
cardiography. However, the threshold of FFR was de-
fined by reference to tests such as stress echocardiogra-
phy.23 Moreover, the differences in sensitivity/specificity 
cannot be the explanation, because, in both our FFR/
iFR-stratified analysis8 and our present stress echocar-
diography–stratified analysis, the variables were treated 
continuously across their entire spectrum and not as a 
mere dichotomy.24
In ORBITA the research stress echocardiography 
(and the previously reported research FFR/iFR) were 
performed after the clinical decision to revascularize. 
These research assessments were not made available to 
the clinicians. Therefore, as might be expected in a trial 
of single-vessel coronary stenoses, many patients had a 
low stress echocardiography score. Nevertheless, there 
was not only a clear reduction of stress echocardiogra-
phy score by PCI, but also a relationship between the 
prerandomization stress echocardiography score and 
the degree of angina relief beyond placebo from PCI.
PCI is known to improve ischemia as assessed by 
DSE.1,11 The COURAGE trial (Clinical Outcomes Utiliz-
ing Revascularization and Aggressive Drug Evaluation), 
which confirmed that PCI reduced ischemia on myo-
cardial perfusion scans,25 showed that the baseline ex-
tent of ischemia did not predict the efficacy of PCI in 
reducing death or myocardial infarction.26 No previous 
studies have assessed the impact of prerandomization 
noninvasive ischemia on the placebo-controlled efficacy 
of PCI on symptom relief. The present analysis shows 
that the greater the degree of stress echocardiography 
ischemia preintervention, the greater the angina relief 
from PCI beyond placebo.
Limitations of This Study
This analysis addresses only the 183 patients from the 
200-patient ORBITA trial with prerandomization DSE. 
There is potential for bias if the remaining 17 patients 
differed in some way.
Our original expectation had been of a large PCI ef-
fect on exercise time. Because this expectation was not 
realized, there is reduced power to detect variation in 
exercise time effect across different prerandomization 
strata. Despite this, there was still a surprisingly clear 
relationship between prerandomization DSE and place-
bo-controlled angina relief.
The follow-up period may be considered short at 6 
weeks. However, the effect of PCI on both angiographic 
and physiological improvement of a stenosis is immedi-
ate, and the primary results of ORBITA showed virtually 
complete normalization of stress echocardiography (as-
sessed blinded to time point) at the 6-week follow-up 
scan. In previous trials, angina relief was seen a month 
post-PCI.2 Therefore, we believe that we should not re-
gard 6-week data as premature.
Stress echocardiography assessment is known to 
have interobserver27 and intraobserver variability.28 To 
reduce the impact of this variability, each scan was re-
ported twice by 6 different operators who were each 
blinded to the treatment allocation and time point of 
the scan and to their own and each other’s opinions. 
Each scan was therefore summarized as the mean of 
12 opinions.
Conclusions
Stratification of the primary and secondary end points 
of ORBITA by prerandomization DSE showed that the 
higher the stress echocardiography score, the greater 
the placebo-controlled efficacy of PCI on improvement 
in patient-reported frequency of angina.
Figure 6. A proposed sequence of steps in the pathway of ischemia. 
Coronary stenosis (step A) causes coronary hemodynamic insufficiency (step B) 
which leads to stress-induced myocardial ischemia. This manifests as wall mo-
tion abnormalities on imaging tests (step C) and causes pain that is verbalized 
by the patient (step D) and recorded by the physician (step E). The magnitude 
of association between measurements is likely to be stronger between adja-
cent steps than steps further apart.
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In ORBITA, the effect of PCI was progressively less 
clear at each step in the chain from anatomy, to invasive 
hemodynamics, to stress echocardiography ischemia, 
and then to the frequency of angina.
We have previously found that there is a clear 
relationship between invasive physiology and stress 
echocardiography score, but no relationship be-
tween invasive physiology and placebo-controlled 
symptom improvement. The present analysis shows 
that there is clear evidence of a relationship be-
tween ischemia on stress echocardiography and the 
placebo-controlled efficacy of PCI on the frequency 
of angina.
ARTICLE INFORMATION
Received July 25, 2019; accepted September 24, 2019.
The online-only Data Supplement is available with this article at https://www.
ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.119.042918.
Authors
Rasha K. Al-Lamee, MA, MBBS, PhD; Matthew J. Shun-Shin, MA, BMBCh, 
PhD; James P. Howard, MA, MBBChir; Alexandra N. Nowbar, BSc, MBBS; 
Christopher Rajkumar, BSc, MBBS; David Thompson, MBBS, PhD; Sayan Sen, 
BSc, MBBS, PhD; Sukhjinder Nijjer, BSc, MBBS, PhD; Ricardo Petraco, MBBS, 
PhD; John Davies, BSc, MBBS, PhD; Thomas Keeble, BSc, MBBS, MD; Kare Tang, 
MBBS; Iqbal Malik, MBBChir, MA, PhD; Nina Bual, MSc; Christopher Cook, BSc, 
MBBS; Yousif Ahmad, BSc, MBBS; Henry Seligman, BA, MBBS; Andrew S.P. 
Sharp, MBChB, MD; Robert Gerber, BSc, MBBS, PhD; Suneel Talwar, MBBS, 
MD; Ravi Assomull, MA, MBBChir, MD; Graham Cole, MA, MBBChir, PhD; 
Niall G. Keenan, MA, BMBCh, MD; Gajen Kanaganayagam, BSc, MBBS, PhD; 
Joban Sehmi, BSc, MBBS, PhD; Roland Wensel, MD, PhD; Frank E. Harrell, Jr., 
PhD; Jamil Mayet, MBChB, MD; Simon Thom, MBBS, MD; Justin E. Davies, BSc, 
MBBS, PhD; Darrel P. Francis, MA, MBBChir, MD
Correspondence
Rasha Al-Lamee, MA, MBBS, PhD, National Heart and Lung Institute, Impe-
rial College London, Hammersmith Hospital, Du Cane Rd, London W10 0HS, 
United Kingdom. Email r.al-lamee13@imperial.ac.uk
Affiliations
National Heart and Lung Institute, Imperial College London, UK (R.K.A-L., 
M.J.S.-S., J.P.H., A.N.N., C.R., D.T., S.S., S.N., R.P., I.M., C.C., Y.A., H.S., G.C., 
R.W., J.M., S. Thom, D.P.F.). Imperial College Healthcare NHS Trust, London, UK 
(R.K.A-L., M.J.S.-S., J.P.H., A.N.N., C.R., S.S., S.N., R.P., I.M., C.C., Y.A., H.S., 
R.A., G.C., G.K., J.M., J.E.D., D.P.F.). Essex Cardiothoracic Centre, Basildon, UK 
(J.D., T.K., K.T.). Anglia Ruskin University, Chelmsford, UK (J.D., T.K.). Cardiff 
Royal Infirmary, UK (A.S.P.S.). East Sussex Healthcare NHS Trust, Hastings, UK 
(R.G.). Royal Bournemouth and Christchurch NHS Trust, UK (S. Talwar). West 
Hertfordshire Hospitals NHS Trust, Watford, UK (N.G.K., J.S.). Vanderbilt Uni-
versity School of Medicine, Department of Biostatistics, Nashville, TN (F.E.H.).
Acknowledgments
ORBITA was an investigator-led trial sponsored by Imperial College London. We 
thank our patients and their families for their dedication and support for the 
ORBITA trial. Special thanks to N. Bual for performing the stress echocardiogra-
phy investigations. We thank the research and administrative teams at Imperial 
College Healthcare NHS Trust, Essex Cardiothoracic Centre, East Sussex Health-
care NHS Trust, Royal Devon and Exeter NHS Trust, and Royal Bournemouth and 
Christchurch NHS Trust for their dedication and support.
Sources of Funding
The trial was funded by grants from National Institute for Health Research 
(NIHR) Imperial Biomedical Research Centre, Foundation for Circulatory Health, 
and Imperial College Healthcare Charity. Dr Howard is a PhD Training Fellow at 
the Wellcome Trust. Philips Volcano supplied the coronary pressure wires. We 
acknowledge the support of the NIHR Clinical Research Network (NIHR CRN).
Disclosures
Drs J. E. Davies and Mayet hold patents pertaining to the iFR technology. Drs J. 
E. Davies and Sharp are consultants for Philips Volcano. Drs Al-Lamee, Sen, Pe-
traco, Cook, and Nijjer have received speaker’s honoraria from Philips Volcano. 
Drs J. E. Davies and Keeble have received research grants from Philips Volcano. 
The other authors report no conflicts.
REFERENCES
 1. Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J, Keeble T, 
Mielewczik M, Kaprielian R, Malik IS, et al; ORBITA Investigators. Per-
cutaneous coronary intervention in stable angina (ORBITA): a double-
blind, randomised controlled trial. Lancet. 2018;391:31–40. doi: 
10.1016/S0140-6736(17)32714-9
 2. Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C, 
Zhang W, Hartigan PM, Lewis C, Veledar E, et al; COURAGE Trial Research 
Group. Effect of PCI on quality of life in patients with stable coronary 
disease. N Engl J Med. 2008;359:677–687. doi: 10.1056/NEJMoa072771
 3. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor  
JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, et al; BARI 
2D Study Group. A randomized trial of therapies for type 2 diabetes 
and coronary artery disease. N Engl J Med. 2009;360:2503–2515. doi: 
10.1056/NEJMoa0805796
 4. De Bruyne B, Fearon WF, Pijls NH, Barbato E, Tonino P, Piroth Z, Jagic N, 
Mobius-Winckler S, Rioufol G, Witt N, et al; FAME 2 Trial Investigators. 
Fractional flow reserve-guided PCI for stable coronary artery disease. N 
Engl J Med. 2014;371:1208–1217. doi: 10.1056/NEJMoa1408758
 5. Windecker S, Stortecky S, Stefanini GG, da Costa BR, Rutjes AW, 
Di Nisio M, Silletta MG, Maione A, Alfonso F, Clemmensen PM, et al. 
Revascularisation versus medical treatment in patients with stable coro-
nary artery disease: network meta-analysis. BMJ. 2014;348:g3859. doi: 
10.1136/bmj.g3859
 6. Wijeysundera HC, Nallamothu BK, Krumholz HM, Tu JV, Ko DT. Meta-
analysis: effects of percutaneous coronary intervention versus medi-
cal therapy on angina relief. Ann Intern Med. 2010;152:370–379. doi: 
10.7326/0003-4819-152-6-201003160-00007
 7. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medi-
cal therapy in the treatment of single-vessel coronary artery disease. Vet-
erans Affairs ACME Investigators. N Engl J Med. 1992;326:10–16. doi: 
10.1056/NEJM199201023260102
 8. Al-Lamee R, Howard JP, Shun-Shin MJ, Thompson D, Dehbi HM, Sen S, 
Nijjer S, Petraco R, Davies J, Keeble T, et al. Fractional flow reserve and 
instantaneous wave-free ratio as predictors of the placebo-controlled 
response to percutaneous coronary intervention in stable single-ves-
sel coronary artery disease. Circulation. 2018;138:1780–1792. doi: 
10.1161/CIRCULATIONAHA.118.033801
 9. Fournier S, Ciccarelli G, Toth GG, Milkas A, Xaplanteris P, Tonino PAL, 
Fearon WF, Pijls NHJ, Barbato E, De Bruyne B. Association of improvement 
in fractional flow reserve with outcomes, including symptomatic relief, af-
ter percutaneous coronary intervention. JAMA Cardiol. 2019;4:370–374. 
doi: 10.1001/jamacardio.2019.0175
 10. Cook CM, Ahmad Y, Howard JP, Shun-Shin MJ, Sethi A, Clesham GJ, 
Tang KH, Nijjer SS, Kelly PA, Davies JR, et al. Association between physi-
ological stenosis severity and angina-limited exercise time in patients 
with stable coronary artery disease. JAMA Cardiol. 2019;4:569–574. doi: 
10.1001/jamacardio.2019.1139
 11. Akosah KO, Porter TR, Simon R, Funai JT, Minisi AJ, Mohanty PK. Ischemia-
induced regional wall motion abnormality is improved after coronary an-
gioplasty: demonstration by dobutamine stress echocardiography. J Am 
Coll Cardiol. 1993;21:584–589. doi: 10.1016/0735-1097(93)90088-i
 12. Harrell FE, Slaughter JC. Biostatistics for Biomedical Research. 2019. 
https://hbiostat.org/doc/bbr.pdf. Accessed October 29, 2019. 
 13. Harrell FE. Regression Modelling Strategies. Cham, Switzerland: Springer 
International Publishing; 2015.
 14. R Development Core Team. A Language And Environment for Statisti-
cal Computing. Vienna, Austria: R Foundation for Statistical Computing; 
2010.
 15. Harrell FE. rms: Regression Modeling Strategies. R package version 3.4.3. 
2018. https://cran.r-project.org/web/packages/rms/rms.pdf. Accessed 
October 29, 2019. 
D
ow
nloaded from
 http://ahajournals.org by on November 14, 2019
Al-Lamee et al Stress Echocardiography-Stratified ORBITA Analysis
xxx xxx, 2019 Circulation. 2019;140:00–00. DOI: 10.1161/CIRCULATIONAHA.119.04291810
OR
IG
IN
AL
 R
ES
EA
RC
H 
AR
TI
CL
E
 16. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York: 
Springer-Verlag; 2009.
 17. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, 
Möbius-Winkler S, Rioufol G, Witt N, et al; FAME 2 Trial Investigators. Frac-
tional flow reserve-guided PCI versus medical therapy in stable coronary dis-
ease. N Engl J Med. 2012;367:991–1001. doi: 10.1056/NEJMoa1205361
 18. Cook CM, Ahmad Y, Howard JP, Shun-Shin MJ, Sethi A, Clesham GJ, Tang KH, 
Nijjer SS, Kelly PA, Davies JR, et al. Impact of percutaneous revasculariza-
tion on exercise hemodynamics in patients with stable coronary disease. J 
Am Coll Cardiol. 2018;72:970–983. doi: 10.1016/j.jacc.2018.06.033
 19. Bech GJ, De Bruyne B, Pijls NH, de Muinck ED, Hoorntje JC, Escaned J, 
Stella PR, Boersma E, Bartunek J, Koolen JJ, et al. Fractional flow reserve 
to determine the appropriateness of angioplasty in moderate coronary 
stenosis: a randomized trial. Circulation. 2001;103:2928–2934. doi: 
10.1161/01.cir.103.24.2928
 20. Ernst E, Resch KL. Concept of true and perceived placebo effects. BMJ. 
1995;311:551–553. doi: 10.1136/bmj.311.7004.551
 21. Ernst E, Resch KL. The importance of placebo effects. JAMA. 1995;273:283; 
author reply 284. doi: 10.1001/jama.1995.03520280027020
 22. Kaptchuk TJ, Goldman P, Stone DA, Stason WB. Do medical devices have 
enhanced placebo effects? J Clin Epidemiol. 2000;53:786–792. doi: 
10.1016/s0895-4356(00)00206-7
 23. Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek J 
Koolen JJ, Koolen JJ. Measurement of fractional flow reserve to as-
sess the functional severity of coronary-artery stenoses. N Engl J Med. 
1996;334:1703–1708. doi: 10.1056/NEJM199606273342604
 24. Giannoni A, Baruah R, Leong T, Rehman MB, Pastormerlo LE, Harrell FE, 
Coats AJ, Francis DP. Do optimal prognostic thresholds in continu-
ous physiological variables really exist? Analysis of origin of apparent 
thresholds, with systematic review for peak oxygen consumption, 
ejection fraction and BNP. PLoS One. 2014;9:e81699. doi: 10.1371/ 
journal.pone.0081699
 25. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, 
Weintraub WS, O’Rourke RA, Dada M, Spertus JA, et al; COURAGE In-
vestigators. Optimal medical therapy with or without percutaneous 
coronary intervention to reduce ischemic burden: results from the Clini-
cal Outcomes Utilizing Revascularization and Aggressive Drug Evaluation 
(COURAGE) trial nuclear substudy. Circulation. 2008;117:1283–1291. 
doi: 10.1161/CIRCULATIONAHA.107.743963
 26. Shaw LJ, Weintraub WS, Maron DJ, Hartigan PM, Hachamovitch R, Min JK, 
Dada M, Mancini GB, Hayes SW, O’Rourke RA, et al. Baseline stress myo-
cardial perfusion imaging results and outcomes in patients with stable 
ischemic heart disease randomized to optimal medical therapy with or 
without percutaneous coronary intervention. Am Heart J. 2012;164:243–
250. doi: 10.1016/j.ahj.2012.05.018
 27. Picano E, Lattanzi F, Orlandini A, Marini C, L’Abbate A. Stress echocardiog-
raphy and the human factor: the importance of being expert. J Am Coll 
Cardiol. 1991;17:666–669. doi: 10.1016/s0735-1097(10)80182-2
 28. Geleijnse ML, Krenning BJ, van Dalen BM, Nemes A, Soliman OI, Bosch JG, 
Galema TW, ten Cate FJ, Boersma E. Factors affecting sensitivity and speci-
ficity of diagnostic testing: dobutamine stress echocardiography. J Am Soc 
Echocardiogr. 2009;22:1199–1208. doi: 10.1016/j.echo.2009.07.006
D
ow
nloaded from
 http://ahajournals.org by on November 14, 2019
